Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATXNASDAQ:EMBCNASDAQ:IRMDNASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.31+7.0%$2.27$1.60▼$16.55$242.21M1.111.06 million shs245,968 shsEMBCEmbecta$10.65+0.4%$11.82$10.20▼$21.48$626.51M1.24467,309 shs4,106 shsIRMDIradimed$60.63+4.9%$52.63$41.69▼$63.29$770.85M0.9143,118 shs51,625 shsRXSTRxSight$15.59-1.4%$15.81$12.53▼$60.81$631.91M1.32696,165 shs10,441 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics+29.29%+28.75%+20.70%+22.13%-77.45%EMBCEmbecta+1.53%-5.77%-16.65%-18.38%-17.24%IRMDIradimed+3.46%+13.78%+11.82%+12.60%+38.02%RXSTRxSight+1.80%-1.25%-0.25%-40.54%-72.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics3.098 of 5 stars4.61.00.00.03.32.50.0EMBCEmbecta4.8641 of 5 stars3.25.03.30.02.73.33.8IRMDIradimed4.7891 of 5 stars2.53.02.54.44.03.31.9RXSTRxSight3.0229 of 5 stars4.21.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.63282.00% UpsideEMBCEmbecta 2.33Hold$19.3381.52% UpsideIRMDIradimed 3.00Buy$72.0018.76% UpsideRXSTRxSight 2.30Hold$37.90143.17% UpsideCurrent Analyst Ratings BreakdownLatest CATX, IRMD, RXST, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective Therapeutics$1.43M171.55N/AN/A$2.67 per share1.24EMBCEmbecta$1.08B0.58$2.47 per share4.32($13.23) per share-0.81IRMDIradimed$75.15M10.26$1.51 per share40.12$5.66 per share10.71RXSTRxSight$148.31M4.27N/AN/A$4.47 per share3.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.723.470.785.25%-19.22%11.92%8/8/2025 (Estimated)IRMDIradimed$19.23M$1.5540.4230.31N/A26.26%24.12%21.20%7/30/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)Latest CATX, IRMD, RXST, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AEMBCEmbecta$0.605.63%N/A66.67%N/AIRMDIradimed$0.681.12%N/A43.87%1 YearsRXSTRxSightN/AN/AN/AN/AN/ALatest CATX, IRMD, RXST, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60EMBCEmbectaN/A2.241.67IRMDIradimedN/A9.217.82RXSTRxSightN/A12.6711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%EMBCEmbecta93.83%IRMDIradimed92.34%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%EMBCEmbecta0.42%IRMDIradimed36.80%RXSTRxSight9.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableIRMDIradimed11012.72 million7.97 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableCATX, IRMD, RXST, and EMBC HeadlinesRecent News About These CompaniesRxSight (NASDAQ:RXST) Stock Price Down 5.5% - What's Next?May 31, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Nuveen Asset Management LLCMay 31, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Investments LPMay 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 46,700 RxSight, Inc. (NASDAQ:RXST)May 28, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by D. E. Shaw & Co. Inc.May 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 74,800 Shares of RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRoyal Bank of Canada Raises Holdings in RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Voloridge Investment Management LLCMay 26, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?May 25, 2025 | marketbeat.comTwinbeech Capital LP Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 25, 2025 | marketbeat.comDo Options Traders Know Something About RxSight Stock We Don't?May 23, 2025 | msn.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Hold" by BrokeragesMay 23, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Invests $2.99 Million in RxSight, Inc. (NASDAQ:RXST)May 22, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Upgraded to Overweight at Wells Fargo & CompanyMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 21, 2025 | marketbeat.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comPolar Asset Management Partners Inc. Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Purchases 39,347 Shares of RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Purchased by Lazard Asset Management LLCMay 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, IRMD, RXST, and EMBC Company DescriptionsPerspective Therapeutics NYSE:CATX$3.34 +0.25 (+8.16%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Embecta NASDAQ:EMBC$10.64 +0.03 (+0.29%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Iradimed NASDAQ:IRMD$60.62 +2.84 (+4.91%) As of 10:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.RxSight NASDAQ:RXST$15.62 -0.20 (-1.23%) As of 10:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
